

# Jack Ansell

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2987816/jack-ansell-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

51  
papers

10,042  
citations

21  
h-index

57  
g-index

57  
ext. papers

11,651  
ext. citations

6  
avg, IF

5.33  
L-index

#	Paper	IF	Citations
51	Virtual Education for Patient Self-Testing for Warfarin Therapy Is Effective During the COVID-19 Pandemic.. <i>Joint Commission Journal on Quality and Patient Safety</i> , <b>2022</b> , 48, 214-214	1.4	0
50	Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants. <i>Blood</i> , <b>2021</b> , 137, 115-125	2.2	12
49	Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	2
48	Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). <i>American Heart Journal</i> , <b>2020</b> , 226, 85-93	4.9	4
47	Reversal of Anticoagulation By Ciraparantag: Time to Onset and Duration of Effect. <i>Blood</i> , <b>2020</b> , 136, 24-24	2.2	1
46	Vitamin K for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and meta-analysis. <i>Blood Advances</i> , <b>2019</b> , 3, 789-796	7.8	15
45	A systematic review and meta-analysis of supplemental education in patients treated with oral anticoagulation. <i>Blood Advances</i> , <b>2019</b> , 3, 1638-1646	7.8	9
44	A Novel Whole Blood Point-of-Care Coagulometer to Measure the Effect of Direct Oral Anticoagulants and Heparins. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2019</b> , 45, 259-263	5.3	9
43	Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). <i>Journal of the American Heart Association</i> , <b>2018</b> , 7,	6	104
42	Defining Minimum Necessary Anticoagulation-Related Communication at Discharge: Consensus of the Care Transitions Task Force of the New York State Anticoagulation Coalition. <i>Joint Commission Journal on Quality and Patient Safety</i> , <b>2018</b> , 44, 630-640	1.4	3
41	Ciraparantag Safely and Effectively Reverses Apixaban and Rivaroxaban in Age-Matched Healthy Volunteers As Measured By Whole Blood Clotting Time. <i>Blood</i> , <b>2018</b> , 132, 987-987	2.2	4
40	Disease understanding in patients newly diagnosed with atrial fibrillation. <i>Heart</i> , <b>2018</b> , 104, 494-501	5.1	15
39	American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. <i>Blood Advances</i> , <b>2018</b> , 2, 3257-3291	7.8	199
38	Thrombophilic Evaluation in Patients with Acute Pulmonary Embolism. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2017</b> , 38, 107-120	3.9	7
37	Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). <i>American Heart Journal</i> , <b>2017</b> , 189, 40-47	4.9	40
36	Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation. <i>Clinical Cardiology</i> , <b>2017</b> , 40, 746-751	3.3	7
35	Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]). <i>American Journal of Cardiology</i> , <b>2017</b> , 119, 1596-1597	3	26

34	Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 525-534	16.2	13
33	Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation. <i>American Journal of Medicine</i> , <b>2017</b> , 130, 449-456	2.4	16
32	International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. <i>American Heart Journal</i> , <b>2017</b> , 194, 132-140	4.9	104
31	Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , <b>2017</b> , 3, 192-197	4.6	38
30	Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 2597-2604	15.1	291
29	How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). <i>American Heart Journal</i> , <b>2016</b> , 181, 145-152	4.9	10
28	Integrating electronic health records in the delivery of optimized anticoagulation therapy. <i>Annals of Pharmacotherapy</i> , <b>2015</b> , 49, 125-6	2.9	
27	Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. <i>American Heart Journal</i> , <b>2015</b> , 170, 141-8, 148.e1	4.9	152
26	Features of electronic health records necessary for the delivery of optimized anticoagulant therapy: consensus of the EHR Task Force of the New York State Anticoagulation Coalition. <i>Annals of Pharmacotherapy</i> , <b>2015</b> , 49, 113-24	2.9	10
25	Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>American Heart Journal</i> , <b>2015</b> , 169, 25-30	4.9	51
24	Bleeding and clotting in hereditary hemorrhagic telangiectasia. <i>World Journal of Clinical Cases</i> , <b>2015</b> , 3, 330-7	1.6	11
23	Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. <i>Circulation</i> , <b>2014</b> , 129, 2005-12	16.7	55
22	Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). <i>American Heart Journal</i> , <b>2014</b> , 167, 735-42.e2	4.9	80
21	Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry. <i>American Heart Journal</i> , <b>2014</b> , 168, 160-7	4.9	53
20	Comment on: editorial by Husted et al. "Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel". ( <i>Thromb Haemost</i> 2014; 111: 781-782). <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 112, 841	7	5
19	Reversal agents in development for the new oral anticoagulants. <i>Postgraduate Medicine</i> , <b>2014</b> , 126, 19-24	4.7	32
18	STABLE results: warfarin home monitoring achieves excellent INR control. <i>American Journal of Managed Care</i> , <b>2014</b> , 20, 202-9	2.1	20
17	Target specific oral anticoagulants in the management of thromboembolic disease in the elderly. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2013</b> , 36, 203-11	5.1	1

16	Point-of-care patient self-monitoring of oral vitamin K antagonist therapy. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2013</b> , 35, 339-41	5.1	6
15	Indirect Comparison Of Dabigatran, Rivaroxaban and Apixaban For Venous Thromboembolic Disease. <i>Blood</i> , <b>2013</b> , 122, 3640-3640	2.2	
14	New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation. <i>Circulation</i> , <b>2012</b> , 125, 165-70; discussion 170	16.7	56
13	New targets for anticoagulation and future perspectives. <i>Current Drug Discovery Technologies</i> , <b>2012</b> , 9, 150-5	1.5	2
12	Apixaban versus warfarin in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 981-92	59.2	5856
11	Correction to lepirudin dosage in table 1 of Direct Thrombin Inhibitors. <i>British Journal of Clinical Pharmacology</i> , <b>2011</b> , 72, 718-718	3.8	2
10	Warfarin versus new agents: interpreting the data. <i>Hematology American Society of Hematology Education Program</i> , <b>2010</b> , 2010, 221-8	3.1	29
9	Anticoagulant Management of Atrial Fibrillation In the United States: Findings From a Large National Database of Clinical Test Results (Quest Diagnostics Health Trends Report).. <i>Blood</i> , <b>2010</b> , 116, 1103-1103	2.2	0
8	Indications for Inferior Vena Cava (IVC) Filter Placement - Assessing Compliance with Accepted Standards Set by Two Professional Societies. <i>Blood</i> , <b>2010</b> , 116, 2553-2553	2.2	
7	The absence of an interaction between warfarin and cranberry juice: a randomized, double-blind trial. <i>Journal of Clinical Pharmacology</i> , <b>2009</b> , 49, 824-30	2.9	36
6	Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <i>Chest</i> , <b>2008</b> , 133, 160S-198S	5.3	1648
5	Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). <i>Journal of Thrombosis and Thrombolysis</i> , <b>2007</b> , 23, 83-91	5.1	108
4	Point-Counter Point: Low Intensity vs Standard Intensity Oral Anticoagulation for Long-Term Prevention of Venous Thromboembolism Recurrence. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2006</b> , 21, 49-49	5.1	
3	A Phase II Randomized, Double-Blind, Eight-Arm, Parallel-Group, Dose-Response Study of Apixaban, a New Oral Factor Xa Inhibitor for the Prevention of Deep Vein Thrombosis in Knee Replacement Surgery - On Behalf of the Apixaban Investigators.. <i>Blood</i> , <b>2006</b> , 108, 574-574	2.2	9
2	The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. <i>Chest</i> , <b>2004</b> , 126, 204S-233S	5.3	852
1	Current options in the prevention of thromboembolic disease. <i>Drugs</i> , <b>2004</b> , 64 Suppl 1, 1-5	12.1	28